Healthcare -
Biotechnology - NASDAQ - US
$ 1.54
-1.28 %
$ 71.9 M
Market Cap
-0.74
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Vigil Neuroscience, Inc.
| Net Income | -84.3 M |
| Depreciation & Amortization | 453 K |
| Capital Expenditures | -5 K |
| Stock-Based Compensation | 10.1 M |
| Change in Working Capital | 22.6 M |
| Others | 22.4 M |
| Free Cash Flow | -51.2 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (84.3) | (82.6) | (68.3) | (43.3) | (28.5) |
| Depreciation & Amortization | 0.5 | 0.4 | 78 K | 28 K | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock Based Compensation | 10.1 | 8.9 | 5.5 | 2.1 | 524 |
| Other Operating Activities | (0.2) | (0.1) | 0.9 | 1.2 | 21.4 |
| Change in Working Capital | 22.6 | 3.1 | (3.3) | 0.6 | 0.8 |
| Cash From Operations | (51.2) | (70.4) | (65.1) | (39.3) | (5.2) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | 5 K | (0.7) | (0.9) | (0.2) | (0.5) |
| Other Items | 8.8 | (64.5) | 0 | 0 | 0 |
| Cash From Investing Activities | 8.8 | (65.1) | (0.9) | (0.2) | (0.5) |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 23 K | 43 K | 38 K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 19.9 | 0.9 | 20.8 | 107.8 | 29.8 |
| Cash From Financing Activities | 29.5 | 0.9 | 161.3 | 107.7 | 29.8 |
| CHANGE IN CASH | |||||
| Net Change In Cash | (13.0) | (134.6) | 95.2 | 68.2 | 24.2 |
| FREE CASH FLOW | |||||
| Free Cash Flow | (51.2) | (71.0) | (66.1) | (39.6) | (5.7) |